Hideki Nagao
Known title: DirectorCIK: 0001315306
Associated companies
Transaction History
| MNOV | ▼ Sell | Open Market | 6,754 | $15K | 11/28/2022 | View on chart |
| MNOV | ▼ Sell | Open Market | 218 | $464 | 11/22/2022 | View on chart |
| MNOV | ▼ Sell | Open Market | 5,365 | $12K | 11/21/2022 | View on chart |
| MNOV | ▼ Sell | Open Market | 309 | $674 | 11/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
MediciNova Stock Drops After Phase 2 Trial Misses Goals
MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.
MediciNova Stock Drops After Phase 2 Trial Misses Goals. MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.